The pentavalent rotavirus vaccine: Discovery to licensure and beyond

Clinical Infectious Diseases

Volumn 45, Issue 12, 2007, Pages 1618-1624

  Heaton, Penny M ^a,b   Ciarlet, Max ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVAVAX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; IPOL; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; WC3 ROTAVIRUS VACCINE;

BREAST FEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG TOLERABILITY; EMERGENCY WARD; FEVER; GASTROENTERITIS; GENETIC REASSORTMENT; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INTUSSUSCEPTION; IRRITABILITY; MEDICAL SOCIETY; NONHUMAN; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; SEROTYPE; SIDE EFFECT; SINGLE DRUG DOSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VOMITING; CHEMISTRY; CLASSIFICATION; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG EFFECT; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL; SEROTYPING;

CLINICAL TRIALS, PHASE III AS TOPIC; DEVELOPING COUNTRIES; DRUG APPROVAL; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEROTYPING;

EID: 40449122586     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522997     Document Type: Review

References (34)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72.
2. Rodriguez WJ, Kim HW, Arrobio JO, et al. Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J Pediatr 1977; 91:188-93.
3. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8.
4. Offit PA. Rotaviruses: immunological determinants of protection against infection and disease. Adv Virus Res 1994; 44:161-202.
5. Ciarlet M, Estes MK. Rotaviruses: basic biology, epidemiology and methodologies. In: Bitton G, ed. Encyclopedia of environmental microbiology, New York: John Wiley, 2002: 2753-73.
6. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56.
7. Clark HF, Offit PA, Ellis RS, et al. The development of a multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174:S73-80.
8. Clark HF, Glass RI, Offit PA. Rotavirus vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999: 987-1005.
9. Rennels MB, Glass, RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the national multicenter trial. Pediatrics 1996; 97:7-13.
10. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-8.
11. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-9.
12. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72.
13. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
14. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
15. Treanor JJ, Clark HF, Pichichero M, et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr Infect Dis J 1995; 14:301-7.
16. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184-90.
17. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 2006; 24:4821-9.
18. Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity, and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J 2003; 22:914-20.
19. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002; 110:e67.
20. Block SL, Vesikari R, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 119:1-8.
21. Vesikari T, Itzler R, Matson DO, et al. A regional analysis of the efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization based on data from 11 countries. Int J Infect Dis (in press).
22. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children. MMWR Recomm Rep 2006; 12:55.
23. Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. MMWR Recomm Rep 1999; 48:1-20.
24. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993; 167:577-83.
25. Velázquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-9.
26. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral vaccines in the United States. Pediatr Infect Dis J 2007; 26::221-7.
27. Centers for Disease Control and Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination - United States, February 1, 2006-February 15, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:218-22.
28. RotaTeq (Rotavirus vaccine, live, oral, pentavalent) [package insert]. Whitehouse, NJ: Merck, 2006.
29. Newman RD, Grupp-Phelan J, Shay DK, Davis RL. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999; 103:e3.
30. Goveia MG, Rodriguez Z, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J (in press).
31. Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ 1998; 76:525-37.
32. Steele AD, Peenze I, de Beer MC, et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 2003; 21:354-60.
33. O'Ryan M, Pérez-Schael I, Mamani N, et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J 2001; 20:685-93.
34. Glass RI, Bresee JS, Turcios R, et al. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192:S160-6.